Correlation between sleep impairment and functional dyspepsia

Zhen-Peng Huang¹,* , Si-Meng Li², Tong Shen² and Yuan-Yuan Zhang³

Abstract
Objective: Sleeping habits may greatly impact the prevalence of functional dyspepsia (FD). This study examined relationships between aspects of sleep impairment and FD.
Methods: This prospective study included university student volunteers. Following enrolment, FD was diagnosed based on the Rome IV criteria, dividing participants into an FD group or controls. The FD group was further subdivided into long-term (disease course >6 months) and short-term (disease course 3–6 months) FD groups. Participants completed the Pittsburgh Sleep Quality Index (PSQI), the Rome IV Diagnostic Questionnaire for Gastrointestinal Disorders in Adults, and a visual analogue scale (VAS).
Results: Out of 418 participants in total, sleep quality, latency, and duration, habitual sleep efficiency, sleep disturbances, sleep medication use, daytime dysfunction, and PSQI scores were higher in the FD groups versus controls. Components of PSQI scores emerged as risk factors, and were higher in the long-term versus short-term dyspepsia group. Moreover, these components were positively correlated with frequency/severity of postprandial distress syndrome and early satiation. Total PSQI scores were positively correlated with VAS scores.
Conclusion: Several PSQI components are associated with FD occurrence, symptom frequency, and symptom severity.

Keywords
Functional dyspepsia, sleep impairment, gastrointestinal symptoms

Date received: 31 January 2020; accepted: 4 June 2020

¹Guangzhou Institute of Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong Province, China
²College of Pharmacy, Xi'an Medical University, Xi'an, Shaanxi Province, China
³College of Stomatology, Xi'an Medical University, Xi'an, Shaanxi Province, China

*These data were presented as an abstract at Digestive Disease Week meeting, San Diego, CA, USA, 18–21 May 2019.
Corresponding author:
Zhen-Peng Huang, Guangzhou Institute of Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, 78 Hengzhiyang Rd, Yuexiu District, Guangzhou, Guangdong, 510095, China.
Email: huang_zhenpeng@126.com
Introduction

Functional dyspepsia (FD) is highly prevalent worldwide, with a prevalence that varies between regions. For example, in Western countries the prevalence of FD ranges between 10% and 40%, and in Asia, it ranges between 5% and 30%.\textsuperscript{1,2} Although FD rarely leads to mortality, it can strongly affect quality of life,\textsuperscript{3,4} however, an effective treatment to manage this disease remains unavailable.\textsuperscript{5} The first Rome classification system for functional gastrointestinal disorders was published in 1990, and subsequently the Rome I, Rome II, and Rome III classifications were published in 1992, 1999, and 2006, respectively.\textsuperscript{6} With publication of the Rome IV classification in 2016, the definition of FD was further clarified.\textsuperscript{7}

Sleep impairment is a common medical issue within the general population worldwide, and previously published studies have demonstrated a strong association between sleep impairments and functional gastrointestinal disorders, such as FD and irritable bowel syndrome.\textsuperscript{8,9} For instance, in one study, 68% of patients with FD reported poor sleep quality.\textsuperscript{10} Studies that include self-reported sleep and gastrointestinal symptoms often measure sleep impairment using the Pittsburgh Sleep Quality Index (PSQI), a well-validated measure of perceived sleep quality. Components of the PSQI include subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.\textsuperscript{11} However, the question of whether sleep impairment is independently associated with the development of FD remains unresolved. Additionally, the relationship between facets of sleep impairment risk factors and the physical symptoms of FD also remains unknown.

The aim of the present study was to identify risk factors of sleep impairment and development of FD, and to identify how sleep impairment may contribute to gastrointestinal symptoms in patients with FD.

Participants and methods

Study population

This prospective study was conducted at Xi’an Medical University, Xi’an, Shaanxi, China, between January 2018 and October 2018. Individuals interested in participating were recruited from the student population of Xi’an Medical University, through flyers, emails, and student unions. Participation in this study was voluntary, and questionnaires and study information were anonymized. Individuals were informed that participation would not affect course grades, and participants were compensated with a free health consultation provided by the researchers.\textsuperscript{12} The study was approved by the Institutional Ethics Committee of Xi’an Medical University (Xi’an, Shaanxi, China; approval date, 8 July 2017). Written informed consent was obtained from all participants before beginning the study, and the study was compliant with relevant Equator network guidelines.

Participants completed questionnaires, including the Rome IV criteria that was used to diagnose FD. Participants also underwent examinations including electrocardiogram, abdominal ultrasound, X-ray scan, and routine blood tests in order to exclude other diseases. For analysis, participants were subdivided into those with or without FD.

Students who volunteered to participate in the study were included unless they met the following exclusion criteria: other organ system disease that may affect the study results, current pregnancy, currently lactating, or unwilling to participate.
Questionnaires

The PSQI, Rome IV Diagnostic Questionnaire for Gastrointestinal Disorders in Adults, and a visual analogue scale (VAS) were used in the study. All participants were given the approved PSQI, which is a 19-item self-rated questionnaire measuring perceived sleep quality. The PSQI differentiates between poor and good sleep quality by considering seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction over a one-month period. Answers are scored based on a 1–4 Likert-scale, where an overall sum ≥5 indicates poor sleep quality.11

The Rome IV Diagnostic Questionnaire for Gastrointestinal Disorders in Adults was used to classify FD gastrointestinal symptoms. Questionnaires were also administered to measure postprandial distress syndrome and epigastric pain syndrome, including postprandial fullness, early satiation, epigastric pain that had occurred in the last 3 months, and to establish the time duration of the disease.13 Postprandial fullness was evaluated on a scale including little impact on daily life, affecting diet and daily life but not sleep, and seriously affecting sleep. Early satiation severity was evaluated as mild, moderate, or severe.

The VAS was used to measure severity of epigastric pain, and comprised a 10-cm scale, with marks for numbers ranging from 0–10, with 0 indicating no pain, 1–3 indicating mild pain, 4–6 indicating moderate pain, 7–9 indicating severe pain, and 10 indicating pain so severe as to be unbearable.14

Specialist doctors (ZPH, SML, TS and YYZ) used a standard explanation to describe the tests, so that the participants were able to complete the questionnaires independently, without external interference, and with a time restriction of completion within 30 min from the start of the test. The doctors then calculated the PSQI and VAS scores from completed questionnaires.

Statistical Analyses

All statistical analyses were performed using SPSS software for Windows, version 17.0 (SPSS Inc., Chicago, IL, USA). Continuous variables are presented as mean ± SD and categorical variables are presented as proportions and percentages. Student’s t-test was used to compare continuous variables, and χ²-test of independence was used to compare categorical variables. Multivariate logistic regression analysis and Spearman’s correlation coefficient test were also conducted. A two-sided P-value < 0.05 was considered to be statistically significant.

Results

Prevalence of FD

According to the formula of sample size estimation used in medical research \( N = \frac{Z^2_1-a/2(1-p)}{e^2p} \), the average prevalence of FD in Asia is approximately 20%. Therefore, a sample size of at least 308 participants was required for the present study.1,2

A total of 418 participants were enrolled into the study, and comprised 130 male and 288 female participants aged 18–25 years (mean age, 20.97 ± 1.07 years). Among the participants, 145 (34.69%) were diagnosed with FD, including 40 (27.6%) males and 105 (72.4%) females. There was no statistically significant difference in the proportions of males and females with or without FD (\( P = 0.269 \)).

Sleep impairment and incidence of FD

All PSQI score components (i.e. subjective sleep quality, sleep latency, sleep duration,
habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction), and PSQI total scores, were significantly higher in the FD group than in the control group (all $P < 0.05$; Figure 1).

Moreover, multivariate logistic regression analysis showed that subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, daytime dysfunction, and total PSQI scores, were significant risk factors for FD (all $P < 0.05$; Table 1).

Sleep impairment and development of FD

The FD group was further subdivided into two groups according to the duration of FD gastrointestinal symptoms: Long-term FD, defined as FD gastrointestinal symptoms lasting more than 6 months ($n = 55$); and short-term FD, defined as FD gastrointestinal symptoms lasting 3–6 months ($n = 90$).

In the long-term FD group, PSQI scores for subjective sleep quality, sleep latency, sleep disturbances, use of sleeping medication, daytime dysfunction, and PSQI total score were all higher than in the short-term FD group (all $P < 0.05$; Figure 2). There was no statistically significant between-group difference in PSQI scores for sleep duration and habitual sleep efficiency ($P > 0.05$).

Sleep impairment and gastrointestinal symptoms of FD

The gastrointestinal symptoms analysed included postprandial fullness and early satiation (defined as postprandial distress syndrome), and epigastric pain (defined as epigastric pain syndrome). PSQI scores, including subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, daytime dysfunction, and total scores were all higher in participants with gastrointestinal symptoms compared with the control group (all $P < 0.05$; Figure 3).

Regarding postprandial distress syndrome (postprandial fullness and early satiation), PSQI scores, including subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, daytime dysfunction, and total scores were all higher in the FD group versus healthy controls. *$P < 0.05$, FD group versus healthy controls.

Figure 1. Pittsburgh Sleep Quality Index (PSQI) scores between healthy adults ($n = 273$) and those with functional dyspepsia (FD, $n = 145$). All PSQI score components (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction), and total PSQI score, were higher in the FD group versus healthy controls. *$P < 0.05$, FD group versus healthy controls.
satiation), various aspects of sleep quality were further evaluated using Spearman’s correlation coefficient. Subjective sleep quality, sleep latency, sleep disturbances, daytime dysfunction and total scores were positively correlated with the frequency of postprandial fullness (all $P < 0.05$; Table 2). Additionally, subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, daytime dysfunction, and total scores were positively correlated with the severity of postprandial fullness (all $P < 0.05$; Table 2). Subjective sleep quality, sleep disturbances, and total scores were positively correlated with the frequency of early satiation. In addition, subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, daytime dysfunction, and PSQI total scores were all positively correlated with the severity of early satiation (all $P < 0.05$; Table 2).

Regarding epigastric pain syndrome, sleep disturbances were positively correlated with the frequency of epigastric pain. Subjective sleep quality, sleep latency, sleep duration, sleep disturbances, daytime dysfunction, and PSQI total scores were all positively correlated with the VAS scale for pain severity (all $P < 0.05$; Table 3).

| PSQI sleep impairment factor       | Odds ratio | 95% CI         | Statistical significance |
|-----------------------------------|------------|----------------|--------------------------|
| Subjective sleep quality          | 1.612      | 1.109, 2.345   | $P = 0.012$              |
| Sleep latency                     | 1.753      | 1.344, 2.287   | $P < 0.001$              |
| Sleep duration                    | 1.933      | 1.345, 2.776   | $P < 0.001$              |
| Habitual sleep efficiency         | 11.611     | 6.844, 19.698  | $P < 0.001$              |
| Sleep disturbances                | 4.343      | 2.181, 8.648   | $P < 0.001$              |
| Use of sleeping medication        | 3.896      | 0.825, 18.404  | $P < 0.001$              |
| Daytime dysfunction               | 2.623      | 1.801, 3.821   | $P < 0.001$              |
| PSQI total scores                 | 4.489      | 3.253, 6.193   | $P < 0.001$              |

PSQI, Pittsburgh Sleep Quality Index; CI, confidence interval.

Figure 2. Pittsburgh Sleep Quality Index (PSQI) scores between adults with long-term functional dyspepsia (FD, $n = 55$) and those with short-term FD ($n = 90$). In the long-term FD group, PSQI scores for subjective sleep quality, sleep latency, sleep disturbances, use of sleeping medication, daytime dysfunction, and PSQI total score were all higher in the long-term FD group versus the short-term FD group (all $P < 0.05$). There were no statistically significant between-group differences in PSQI scores for sleep duration and habitual sleep efficiency.
Discussion

Functional dyspepsia is a functional gastrointestinal disorder characterized by the absence of organic changes. The underlying mechanism of FD remains unknown, but it is a very common ailment in the global population, with a prevalence that varies between 7% and 45% worldwide. A large-scale study in France concluded that the prevalence of FD was about 15–21%, while in Korea, the prevalence of FD is

Figure 3. Pittsburgh Sleep Quality Index (PSQI) scores between adults with functional dyspepsia gastrointestinal symptoms and healthy controls: (A) PSQI scores between adults with postprandial fullness (n = 101) and healthy participants (n = 273); (B) PSQI scores between adults with early satiation (n = 92) and healthy participants (n = 273); and (C) PSQI scores between adults with epigastric pain (n = 58) and healthy participants (n = 273). *P < 0.05 versus healthy controls.
### Table 2. Correlation between components of sleep impairment and postprandial distress syndrome symptoms (postprandial fullness and early satiation).

| Parameter                        | Postprandial fullness | Early satiation |
|----------------------------------|------------------------|-----------------|
|                                  | \( r \) | Statistical significance | \( r \) | Statistical significance |
| Gastrointestinal Symptom Frequency |                        |                 |                 |
| Subjective Sleep Quality         | 0.231 | \( P = 0.020 \) | 0.252 | \( P = 0.015 \) |
| Sleep Latency                    | 0.205 | \( P = 0.039 \) | 0.198 | NS                  |
| Sleep Duration                   | 0.028 | NS                  | -0.085 | NS                  |
| Habitual Sleep Efficiency        | -0.030 | NS                  | -0.050 | NS                  |
| Sleep Disturbances               | 0.337 | \( P = 0.001 \) | 0.293 | \( P = 0.005 \) |
| Use of Sleeping Medication       | 0.011 | NS                  | 0.071 | NS                  |
| Daytime Dysfunction              | 0.247 | \( P = 0.013 \) | 0.160 | NS                  |
| PSQI Total Scores                | 0.304 | \( P = 0.002 \) | 0.227 | \( P = 0.029 \) |
| Gastrointestinal Symptom Severity|                        |                 |                 |
| Subjective Sleep Quality         | 0.480 | \( P < 0.001 \) | 0.359 | \( P < 0.001 \) |
| Sleep Latency                    | 0.522 | \( P < 0.001 \) | 0.418 | \( P < 0.001 \) |
| Sleep Duration                   | 0.277 | \( P = 0.005 \) | 0.303 | \( P = 0.003 \) |
| Habitual Sleep Efficiency        | 0.265 | \( P = 0.007 \) | 0.282 | \( P = 0.007 \) |
| Sleep Disturbances               | 0.402 | \( P < 0.001 \) | 0.345 | \( P < 0.001 \) |
| Use of Sleeping Medication       | 0.131 | NS                  | 0.044 | NS                  |
| Daytime Dysfunction              | 0.387 | \( P < 0.001 \) | 0.381 | \( P < 0.001 \) |
| PSQI Total Scores                | 0.670 | \( P < 0.001 \) | 0.600 | \( P < 0.001 \) |

PSQI, Pittsburgh Sleep Quality Index; NS, no statistically significant correlation \( (P > 0.05) \).

### Table 3. Correlation between components of sleep impairment and epigastric pain syndrome.

| Parameter                        | \( r \) | Statistical significance |
|----------------------------------|----------|--------------------------|
| Epigastric Pain Frequency        |          |                          |
| Subjective Sleep Quality         | 0.105    | NS                       |
| Sleep Latency                    | 0.196    | NS                       |
| Sleep Duration                   | -0.214   | NS                       |
| Habitual Sleep Efficiency        | 0.110    | NS                       |
| Sleep Disturbances               | 0.354    | \( P = 0.006 \)          |
| Use of Sleeping Medication       | -0.103   | NS                       |
| Daytime Dysfunction              | 0.223    | NS                       |
| PSQI Total Scores                | 0.257    | NS                       |
| Pain VAS                         |          |                          |
| Subjective Sleep Quality         | 0.544    | \( P < 0.001 \)          |
| Sleep Latency                    | 0.451    | \( P < 0.001 \)          |
| Sleep Duration                   | 0.265    | \( P = 0.045 \)          |
| Habitual Sleep Efficiency        | 0.256    | NS                       |
| Sleep Disturbances               | 0.603    | \( P < 0.001 \)          |
| Use of Sleeping Medication       | 0.104    | NS                       |
| Daytime Dysfunction              | 0.288    | \( P = 0.028 \)          |
| PSQI Total Scores                | 0.804    | \( P < 0.001 \)          |

PSQI, Pittsburgh Sleep Quality Index; VAS, visual analogue scale.
NS, no statistically significant correlation \( (P > 0.05) \).
thought to be approximately 46.5%. In China, multicentre FD prevalence studies are lacking. In the present single-centre young adult study population, the prevalence of FD was found to be 34.69%, which is within the range reported by previously published studies. 

Sleep impairments severely affect quality of life in adults, and functional gastrointestinal disorders, including FD and irritable bowel syndrome, are common clinical diseases, often accompanied by sleep disorders. Associations between poor sleep quality and functional gastrointestinal disorders have been evaluated in previous studies. Correctly identified and promptly managed sleep impairments may greatly improve gastrointestinal symptoms and quality of life in patients with FD. However, whether sleep impairment is independently associated with the development of FD, and the relationship between sleep impairments and FD gastrointestinal symptoms, remains unknown.

The PSQI is a self-rated questionnaire measuring an individual’s recent history of sleep quality and duration during the last month, and has been well validated and widely used for measuring sleep impairment in patients with functional gastrointestinal disorders. In the present study, sleep impairments were confirmed to be common in patients with FD, similar to the findings from previous studies. Additionally, subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction were found to be worse in patients with FD than in control participants. In patients with longer-term FD (more than 6 months duration), subjective sleep quality, sleep latency, sleep disturbances, use of sleeping medication, daytime dysfunction, and PSQI total score were found to be significantly higher than in those with shorter-term FD, suggesting that factors relating to sleep quality deteriorate with the development of FD. As observed in the present study, subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction were all risk factors for FD. FD has an impact on the sleep-wake cycle and causes poor sleep quality, and conversely, poor sleep strongly promotes the development of FD. Since the gut-brain axis has feedback loops that may influence sleep regulation pathways through immune activation, intestinal permeability, and enteroendocrine signalling, any disturbances in these processes may also contribute to impaired sleep quality in patients with FD.

In the present study, sleep impairment was also found to be positively correlated with specific FD symptoms, including postprandial distress syndrome and epigastric pain syndrome, in terms of both their frequency and severity. Gastrointestinal symptoms such as postprandial fullness, early satiation, epigastric pain in postprandial distress syndrome and epigastric pain syndrome, were found to be associated with decreased subjective sleep quality, prolonged sleep latency, shortened sleep duration, and decreased habitual sleep efficiency. Recent studies have also confirmed that both rapid eye movement sleep and slow wave sleep in patients with FD are decreased. As cytokines may modulate the sleep-wake cycle, sleep disturbances may upregulate proinflammatory cytokines, such as tumour necrosis factor-α, interleukin-1 and interleukin-6, which can have a profound impact on FD symptoms.

The results of the present study may be limited by several factors. The study was conducted at a single centre with a relatively small sample size of volunteers, which may have introduced some sample bias and may limit the generalisability of the present findings. Further studies are required to validate the present results.
In conclusion, the present study found that sleep impairments, evaluated on the basis of subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction, are common in patients with FD. Subjective sleep quality, sleep latency, reduced sleep duration, habitual sleep efficiency, sleep disturbances, increased use of sleeping medication, and daytime dysfunction were found to be risk factors of FD. Sleep impairment was also positively correlated with the frequency and severity of FD gastrointestinal symptoms, including postprandial distress syndrome and epigastric pain syndrome. These results suggest that FD may be prevented by ameliorating sleep impairments.

Acknowledgements
We should like to thank Prof. Hui-Min Wang for his assistance in this study.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
This work was supported by a grant from the Guangzhou key medical discipline construction project fund to Zhen-Peng Huang.

ORCID iD
Zhen-Peng Huang https://orcid.org/0000-0003-2099-9328

References
1. Mahadeva S and Ford AC. Clinical and epidemiological differences in functional dyspepsia between the East and the West. Neurogastroenterol Motil 2016; 28: 167–174.
2. Enck P, Azpiroz F, Boeckxstaens G, et al. Functional dyspepsia. Nat Rev Dis Primers 2017; 3: 17081.
3. Hou ZK, Mi H, Liu FB, et al. Interpreting the Chinese version of quality of life questionnaire for functional digestive disorders. J Gastroenterol Hepatol 2018; 33: 869–877.
4. Lee SW, Lee TY, Lien HC, et al. The risk factors and quality of life in patients with overlapping functional dyspepsia or peptic ulcer disease with gastroesophageal reflux disease. Gut Liver 2014; 8: 160–164.
5. Lee H, Jung HK, Huh KC, et al. Current status of functional dyspepsia in Korea. Korean J Intern Med 2014; 29: 156–165.
6. Talley NJ and Ford AC. Functional dyspepsia. N Engl J Med 2015; 373: 1853–1863.
7. Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology 2016; 150: 1380–1392.
8. Morito Y, Aimi M, Ishimura N, et al. Association between sleep disturbances and abdominal symptoms. Intern Med 2014; 53: 2179–2183.
9. Lei WY, Chang WC, Wong MW, et al. Sleep disturbance and its association with gastrointestinal symptoms/diseases and psychological comorbidity. Digestion 2019; 99: 205–212.
10. Fass R, Fullerton S, Tung S, et al. Sleep disturbances in clinic patients with functional bowel disorders. Am J Gastroenterol 2000; 95: 1195–2000.
11. Buyse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193–213.
12. Leentjens AF and Levenson JL. Ethical issues concerning the recruitment of university students as research subjects. J Psychosom Res 2013; 75: 394–398.
13. Whitehead WE. Rome IV diagnostic questionnaire for adults functional gastrointestinal disorders. Raleigh, North Carolina: The Rome Foundation, 2016, pp.149–187.
14. Bourdel N, Alves J, Pickering G, et al. Systematic review of endometriosis pain assessment: how to choose a scale? Hum Reprod Update 2015; 21: 136–152.
15. Tomita T, Oshima T and Miwa H. New approaches to diagnosis and treatment of functional dyspepsia. Curr Gastroenterol Rep 2018; 20: 55.
16. Forssmann K, Meier L, Uehleke B, et al. A non-interventional, observational study
of a fixed combination of pepsin and amino acid hydrochloride in patients with functional dyspepsia. *BMC Gastroenterol* 2017; 17: 123.

17. Mahadeva S and Goh KL. Epidemiology of functional dyspepsia: a global perspective. *World J Gastroenterol* 2006; 12: 2661–2666.

18. Ghoshal UC, Singh R, Chang FY, et al. Epidemiology of uninvestigated and functional dyspepsia in Asia: facts and fiction. *J Neurogastroenterol Motil* 2011; 17: 235–244.

19. Le Pluart D, Sabaté JM, Bouchoucha M, et al. Functional gastrointestinal disorders in 35,447 adults and their association with body mass index. *Aliment Pharmacol Ther* 2015; 41: 758–767.

20. Huang ZP, Yang XF, Lan LS, et al. Correlation between social factors and anxiety-depression in function dyspepsia: do relationships exist? *Prz Gastroenterol* 2014; 9: 348–353.

21. Zhao W, Jin H, Xu M, et al. Sleep quality of functional gastrointestinal disorder patients in class-three hospitals: a cross-sectional study in Tianjin, China. *Biomed Res Int* 2018; 2018: 3619748.

22. Liu TZ, Xu C, Rota M, et al. Sleep duration and risk of all-cause mortality: a flexible, non-linear, meta-regression of 40 prospective cohort studies. *Sleep Med Rev* 2017; 32: 28–36.

23. Li Y, Gong Y, Li Y, et al. Sleep disturbance and psychological distress are associated with functional dyspepsia based on Rome III criteria. *BMC Psychiatry* 2018; 18: 133.

24. Lacy BE, Everhart K and Crowell MD. Functional dyspepsia is associated with sleep disorders. *Clin Gastroenterol Hepatol* 2011; 9: 410–414.

25. Futagami S, Shimpuku M, Yamawaki H, et al. Sleep disorders in functional dyspepsia and future therapy. *J Nippon Med Sch* 2013; 80: 104–109.

26. Bouchoucha M, Mary F, Bon C, et al. Sleep quality and functional gastrointestinal disorders. A psychological issue. *J Dig Dis* 2018; 19: 84–92.

27. Kim SY, Choung RS, Lee SK, et al. Self-reported sleep impairment in functional dyspepsia and irritable bowel syndrome. *J Neurogastroenterol Motil* 2018; 24: 280–288.

28. Ali T, Choe J, Awab A, et al. Sleep, immunity and inflammation in gastrointestinal disorders. *World J Gastroenterol* 2013; 19: 9231–9239.

29. Matsuzaki J, Suzuki H, Togawa K, et al. Burden of impaired sleep quality on work productivity in functional dyspepsia. *United European Gastroenterol J* 2018; 6: 398–406.

30. Pigarev IN and Pigareva ML. Association of sleep impairments and gastrointestinal disorders in the context of the visceral theory of sleep. *J Integr Neurosci* 2017; 16: 143–156.

31. Miwa H, Minoo T, Hojo M, et al. Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux diseases. *Aliment Pharmacol Ther* 2004; 20: 112–117.

32. Onen SH, Alloui A, Gross A, et al. The effects of total sleep deprivation, selective sleep interruption and sleep recovery on pain tolerance thresholds in healthy subjects. *J Sleep Res* 2001; 10: 35–42.

33. Ohayon MM. Relationship between chronic painful physical condition and insomnia. *J Psychiatr Res* 2005; 39: 151–159.

34. Parekh PJ, Oldfield EC 4th and Johnson DA. Wake-up call to clinicians: the impact of sleep dysfunction on gastrointestinal health and disease. *J Clin Gastroenterol* 2018; 52: 194–203.

35. Santos RV, Tufik S and De Mello MT. Exercise, sleep and cytokines: is there a relation? *Sleep Med Rev* 2007; 11: 231–239.

36. Reinhardt ÉL, Fernandes PA, Markus RP, et al. Short sleep duration increases salivary IL-6 production. *Chronobiol Int* 2016; 33: 780–782.